Transforming cell therapy manufacturing: smart automation & genetic modification for scalable success

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In-process monitoring of critical process parameters (CPP) is a universal requirement and often cost-driving feature of cell manufacturing. Solutions for closed, automated CPP monitoring are in high demand, yet the successful integration of analytical capabilities as PATs into the cell production workflow is challenged by the limited versatility of bioreactor platforms.

Non-viral genetic modification processes apply external equipment (e.g. Nucleofector® Systems) that requires manual fluid transfers. Ideally a bioreactor platform should provide reliable, closed and automated transfer of target cells.

In this webinar we present how the Lonza Cocoon® Platform demonstrates compatibility with off-the-shelf 908 Devices MAVEN Process Analytical Technology (PAT) analyzer and electroporation using the Lonza Nucleofector® System, enabling closed and automated in-process CPP monitoring and genetic modifications.

Attend this webinar to learn about:

• High fidelity, non-invasive in-process sampling of Cocoon® Platform bioreactor and precision delivery of small, representative samples to external devices in a closed and automated manner.
• Proven compatibility to establish at-line connection with off-the-shelf 908 Devices MAVEN process analytical devices (PTA) to functionally integrate CPP monitoring into the Cocoon® Platform bioreactor process.
• Precision delivery of cell suspensions formulated in the Cocoon® Platform for genetic modification in at-line integrated electroporation unit (Lonza Nucleofector® System)

Peter Szaraz

Senior Scientist at Lonza

Peter Szaraz received his PhD in Molecular Medicine at the University of Siena in 2010. After his Post-doctoral studies at the Department of Physiology at the University of Toronto he worked on the development and clinical translation of cardiovascular regenerative therapies till 2020. He has been a Senior Scientist at Lonza for the past 5 years, working predominantly on the Cocoon® platform for CAR-T therapies.

Tessel Hammink

Director of Strategic Partnerships at 908 Devices

Tessel serves as the Director of Strategic Partnerships at 908 Devices, a leading company in the development of cutting-edge process analytical tools. With a strong foundation built upon 14 years of experience in the analytical technology sector, her focus is on forging and nurturing strategic partnerships to accelerate innovation and expand the reach and impact of pioneering solutions. Tessel's approach is rooted in building trust and fostering collaborative environments that lead to sustained growth and success.

Watch now

SPEAKERS

Peter Szaraz

Senior Scientist at Lonza

Tessel Hammink

Director of Strategic Partnerships at 908 Devices

You might also like

Next-gen cell therapy manufacturing: leveraging flexibility and automation for success

F Parietti, D Shaw, C Dargitz

6 March

Watch

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

John Bowen, Brian Tomkowicz

2 April

in 4

Days

Register

Streamlining immune cell therapy manufacturing workflows with single-use cytokines

Gabriella Perell

19 June 2024

Watch

Optimizing iPSC therapies: strategies for safe, cost-effective, and scalable manufacturing

K Bruce, K Bharti, I Barbaric et al.

23 April

in 25

Days

Register